Pharmacokinetics and biodistribution of genetically engineered antibodies
- 7 December 2002
- journal article
- review article
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 13 (6), 603-608
- https://doi.org/10.1016/s0958-1669(02)00352-x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Monoclonal antibodies to target epidermal growth factor receptor–positive tumorsCancer, 2002
- IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancerExpert Opinion on Biological Therapy, 2001
- Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49Critical Reviews in Oncology/Hematology, 2001
- Tumor Targeting of Radiometal Labeled Anti-CEA Recombinant T84.66 Diabody and T84.66 Minibody: Comparison to Radioiodinated FragmentsBioconjugate Chemistry, 2001
- Recombinant antibodies: a novel approach to cancer diagnosis and therapyExpert Opinion on Investigational Drugs, 2000
- Divalent Forms of CC49 Single-Chain Antibody Constructs in Pic) pastoris: Expression, Purification, and CharacterizationThe Journal of Biochemistry, 2000
- Chemical Modification to Reduce Renal Uptake of Disulfide-Bonded Variable Region Fragment of Anti-Tac Monoclonal Antibody Labeled with 99mTcBioconjugate Chemistry, 1999
- A CDR-Grafted (Humanized) Domain-Deleted Antitumor AntibodyCancer Biotherapy & Radiopharmaceuticals, 1997
- Generation, Characterization, andin VivoStudies of Humanized Anticarcinoma Antibody CC49Hybridoma, 1995
- Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.Proceedings of the National Academy of Sciences, 1990